

## Appendix 6 – Adverse Events

**Table 1. Primary Adverse Events (Overall, Serious and Withdrawals due to Adverse Events)**

Adverse Event	Intervention *	Systematic Review (Author, Year)	RCTs included	Sample Size (n)	Outcome Measured at (weeks)	Intervention (%)	Control (%)	RR/OR/HR (95% CI)
<b>Adverse Events-Overall</b>	Bile Acid Sequestrants	Hansen, 2017	13	2714	NR	NR	NR	RR 1.09 (1.02, 1.17)
	Ezetimibe	NR	NR	NR	NR	NR	NR	NR
	Fibrates	NR	NR	NR	NR	NR	NR	NR
	Niacin	NR	NR	NR	NR	NR	NR	NR
	Omega 3s (EPA+DHA)	NR	NR	NR	NR	NR	NR	NR
	EPA only	NR	NR	NR	NR	NR	NR	NR
	PCSK9 Inhibitors	Bai, 2018	10	37219	NR	15501/20258=7 6.5%	12976/16961=7 6.5%	RR 1.01 (1.00-1.02)
	PCSK9 Inhibitors	Mu, 2020	23	NR	NR	NR	NR	RR 1.00 (0.98-1.02)
	PCSK9 Inhibitors	Turgeon, 2018	21	59536	NR	24026/31867=7 5.4%	21057/27669=7 6.1%	RR 1.01 (0.98, 1.03)
	PCSK9 Inhibitors	Wang, 2021	13	24748	NR	9996/13212=75 .7%	8953/11536=77 .6%	RR 0.99 (0.97-1.00)
	PCSK9 Inhibitors	Zhao, 2020	8	49158	NR	18740/24805=7 5.5%	18556/24353=7 6.2%	RR 0.99 (0.98-1.00)
	Statins	Taylor, 2013	12	40716	NR	5748/20718= 27.7%	5090/19998= 25.4%	RR 1.00 (0.97-1.03)
	Statins	Zhou, 2020	6	3254	52-209	581/1694= 34.3%	468/1560= 30%	RR 0.99 (0.95, 1.04)
<b>Serious Adverse Events</b>	Bile Acid Sequestrants	Hansen, 2017	9	2484	NR	NR	NR	RR 1.56 (1.01-2.40)
	Ezetimibe	NR	NR	NR	NR	NR	NR	NR

	Fibrates	NR	NR	NR	NR	NR	NR	NR
	Niacin	NR	NR	NR	NR	NR	NR	NR
	Omega 3s (EPA+DHA)	NR	NR	NR	NR	NR	NR	NR
	EPA only	NR	NR	NR	NR	NR	NR	NR
	PCSK9 Inhibitors	Bai, 2018	10	37219	NR	4183/20258=20 .6%	3802/16961=22 .4%	RR 1.00 (0.96-1.03)
	PCSK9 Inhibitors	Casula, 2019	28	62281	NR	6568/33204=19 .8%	6359/29077=21 .9%	OR 0.95 (0.91-0.99)
	PCSK9 Inhibitors	Karatasakis, 2017	33	44278	NR	4313/24211=17 .8%	3901/20067=19 .4%	OR 0.99 (0.95-1.05)
	PCSK9 Inhibitors	Mu, 2020	22	NR	NR	NR	NR	RR 0.98 (0.95-1.01)
	PCSK9 Inhibitors	Talasz, 2021	7	52965	NR	6374/27048=23 .6%	6351/25917=24 .5%	RR 0.97 (0.93-1.01)
	PCSK9 Inhibitors	Turgeon, 2018	21	59536	NR	6562/31867=20 .6%	6250/27669=22 .6%	RR 0.97 (0.95, 1.00)
	PCSK9 Inhibitors	Wang, 2021	13	24773	NR	2769/13225=20 .9%	2662/11548=23 .1%	RR 0.94 (0.90-0.99)
	PCSK9 Inhibitors	Zhao, 2020	8	49188	NR	5838/24816=23 .5%	5948/24372=24 .4%	RR 0.97 (0.94-1.01)
	Statins	Singh, 2020	5	42952	NR	2615/21498= 12.2%	2639/21454= 12.3%	RR 0.99 (0.95-1.04)
	Statins	Zhou, 2020	7	15947	52-203	2238/7989= 28%	2270/7958= 28.5%	RR 1.01 (0.97, 1.05)
<b>Withdrawals due to Adverse Events</b>	Bile Acid Sequestrants	Hansen, 2017	9	2501	NR	NR	NR	RR 1.48 (0.91-2.42)
	EPA	RCT: Bhatt, 2019 (REDUCE- IT)	1	8179	255	321/4089=7.9%	335/4090=8.2%	P=0.60

	Ezetimibe	Zhan, 2018	10	21746	NR	212/10943	219/10803	RR 0.91 (0.75-1.09)
	Fibrates	Jakob, 2016	3	4805	104-261	712/2420	622/2385	RR 1.38 (0.71-2.68)
	Niacin	Schandelmaier, 2017	17	33539	26-208	3083/17418	1470/16121	RR 2.17 (1.70-2.77)
	Omega 3s (EPA+DHA)	NR	NR	NR	NR	NR	NR	NR
	EPA only	NR	NR	NR	NR	NR	NR	NR
	PCSK9 Inhibitors	Chaiyasothi, 2019	15	66623	NR	982/34362	811/32260	RR 1.08 (0.98-1.18)
	PCSK9 Inhibitors	Guedeney, 2019	NR	60908	NR	955/32379	771/28529	RR 1.04 (0.95-1.15)
	PCSK9 Inhibitors	Mu, 2020	20	NR	NR	NR	NR	RR 0.99 (0.88-1.10)
	PCSK9 Inhibitors	Turgeon, 2018	20	55289	NR	916/29036	720/26253	RR 1.06 (0.94, 1.21)
	Statins	Palmer, 2014	13	4219	NR	266/2098=12.7%	258/2121=12.2%	RR 1.16 (0.84-1.60)
	Statins	Riaz, 2017	22	129680	213	8872/66024=13.4%	8898/63656=14%	OR 0.99 (0.93, 1.06)
	Statins	Singh, 2020	6	33846	NR	1417/16896=8.4%	1521/16950=9.0%	RR 0.91 (0.69-1.18)
	Statins	Taylor, 2013	9	21642	NR	940/11054=8.5%	973/10588=9.2%	OR 0.86 (0.65-1.12)
	Statins	Yebyo, 2019	18	NR	NR	NR	NR	RR 1.00 (0.83-1.20)
	Statins	Zhou, 2020	8	7842	52-209	149/3961=3.8%	127/3881=3.3%	RR 1.05 (0.83, 1.33)

**Table 2. Other Noteworthy Adverse Events**

<b>Intervention*</b>	<b>Adverse Event</b>	<b>Systematic Review (Author, Year)</b>	<b>RCTs included</b>	<b>Sample Size (n)</b>	<b>Outcome Measured at (weeks)</b>	<b>Intervention (%)</b>	<b>Control (%)</b>	<b>RR/OR/HR (95% CI)</b>
<b>Bile Acid Sequestrants</b>	Drug-related adverse events	Hansen, 2017	13	2655	NR	NR	NR	RR 1.62 (1.20-2.19)
<b>Bile Acid Sequestrants</b>	Constipation	Hansen, 2017	NR	1537	NR	NR	NR	RR 3.13 (1.88-5.21)
<b>Bile Acid Sequestrants</b>	Constipation-Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	39%	10%	NR
<b>Bile Acid Sequestrants</b>	Constipation-Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	8%	4%	NR
<b>Bile Acid Sequestrants</b>	Constipation-Year 1	RCT: Brensike, 1984	1	143	261	2%	0%	NR
<b>Bile Acid Sequestrants</b>	Constipation-Year 5	RCT: Brensike, 1984	1	143	261	5%	4%	NR
<b>Bile Acid Sequestrants</b>	Abdominal Pain- Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	15%	11%	NR
<b>Bile Acid Sequestrants</b>	Abdominal Pain- Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	7%	7%	NR
<b>Bile Acid Sequestrants</b>	Abdominal Pain- Year 1	RCT: Brensike, 1984	1	143	261	2%	0%	NR
<b>Bile Acid Sequestrants</b>	Abdominal Pain- Year 5	RCT: Brensike, 1984	1	143	261	3%	0%	NR

<b>Bile Acid Sequestrants</b>	Belching/ Bloating- Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	27%	16%	NR
<b>Bile Acid Sequestrants</b>	Belching/ Bloating- Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	9%	6%	NR
<b>Bile Acid Sequestrants</b>	Belching/ Bloating- Year 1	RCT: Brensike, 1984	1	143	261	4%	1%	NR
<b>Bile Acid Sequestrants</b>	Belching/ Bloating- Year 5	RCT: Brensike, 1984	1	143	261	5%	5%	NR
<b>Bile Acid Sequestrants</b>	Diarrhea- Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	10%	11%	NR
<b>Bile Acid Sequestrants</b>	Diarrhea- Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	4%	8%	NR
<b>Bile Acid Sequestrants</b>	Gas- Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	32%	26%	NR
<b>Bile Acid Sequestrants</b>	Gas- Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	12%	12%	NR
<b>Bile Acid Sequestrants</b>	Gas- Year 1	RCT: Brensike, 1984	1	143	261	7%	3%	NR
<b>Bile Acid Sequestrants</b>	Gas- Year 5	RCT: Brensike, 1984	1	143	261	5%	7%	NR

<b>Bile Acid Sequestrants</b>	Heartburn- Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	27%	10%	NR
<b>Bile Acid Sequestrants</b>	Heartburn- Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	12%	7%	NR
<b>Bile Acid Sequestrants</b>	Heartburn- Year 1	RCT: Brensike, 1984	1	143	261	2%	0%	NR
<b>Bile Acid Sequestrants</b>	Heartburn- Year 5	RCT: Brensike, 1984	1	143	261	5%	0%	NR
<b>Bile Acid Sequestrants</b>	Nausea- Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	16%	8%	NR
<b>Bile Acid Sequestrants</b>	Nausea- Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	3%	4%	NR
<b>Bile Acid Sequestrants</b>	Vomiting- Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	6%	5%	NR
<b>Bile Acid Sequestrants</b>	Vomiting- Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	2%	3%	NR
<b>Bile Acid Sequestrants</b>	At least 1 GI Side Effect- Year 1	RCT: Lipid Research Clinics Program, 1984	1	3806	386	68%	43%	NR
<b>Bile Acid Sequestrants</b>	At least 1 GI Side Effect- Year 7	RCT: Lipid Research Clinics Program, 1984	1	3806	386	29%	26%	NR
<b>Bile Acid Sequestrants</b>	Drowsiness- Year 1	RCT: Brensike, 1984	1	143	261	3%	0%	NR

<b>Bile Acid Sequestrants</b>	Drowsiness- Year 5	RCT: Brensike, 1984	1	143	261	9%	2%	NR
<b>Bile Acid Sequestrants</b>	Itching- Year 1	RCT: Brensike, 1984	1	143	261	2%	1%	NR
<b>Bile Acid Sequestrants</b>	Itching- Year 5	RCT: Brensike, 1984	1	143	261	2%	0%	NR
<b>Bile Acid Sequestrants</b>	Leg Cramps- Year 1	RCT: Brensike, 1984	1	143	261	6%	3%	NR
<b>Bile Acid Sequestrants</b>	Leg Cramps- Year 5	RCT: Brensike, 1984	1	143	261	9%	2%	NR
<b>Bile Acid Sequestrants</b>	Nervousness- Year 1	RCT: Brensike, 1984	1	143	261	4%	1%	NR
<b>Bile Acid Sequestrants</b>	Nervousness- Year 5	RCT: Brensike, 1984	1	143	261	9%	5%	NR
<b>Bile Acid Sequestrants</b>	Rash- Year 1	RCT: Brensike, 1984	1	143	261	2%	0%	NR
<b>Bile Acid Sequestrants</b>	Rash- Year 5	RCT: Brensike, 1984	1	143	261	2%	0%	NR
<b>Bile Acid Sequestrants</b>	Weakness- Year 1	RCT: Brensike, 1984	1	143	261	2%	0%	NR
<b>Bile Acid Sequestrants</b>	Weakness- Year 5	RCT: Brensike, 1984	1	143	261	5%	0%	NR
<b>Ezetimibe</b>	Myopathy, creatine kinase (CK) level $\geq 10$ xULN with associated muscle symptoms	Zhan, 2018	3	20581	NR	25/10287	19/10294	RR 1.31 (0.72- 2.38)

<b>Ezetimibe</b>	Aminotransferase 3x upper limit	Toyota, 2019	2	19865	NR	252/9931	223/9934	OR 1.31 (0.78-2.19)
<b>Ezetimibe</b>	Hepatopathy	Zhan, 2018	4	20687	NR	264/10342	232/10345	RR 1.14 (0.96-1.35)
<b>Ezetimibe</b>	Rhabdomyolysis	Toyota, 2019	1	12413	NR	2/6199	1/6214	OR 2.01 (0.18-22.12)
<b>Ezetimibe</b>	Rhabdomyolysis	Zhan, 2018	2	19865	NR	15/9931	19/9934	RR 0.79 (0.40-1.55)
<b>Ezetimibe</b>	Cancer	Zhan, 2018	5	20455	NR	783/10218	777/10237	RR 1.01 (0.92-1.11)
<b>Ezetimibe</b>	Gallbladder-related Adverse Events	Zhan, 2018	3	20024	NR	293/10038	332/9986	RR 0.88 (0.75-1.03)
<b>Fibrates</b>	Raised Serum Creatinine	Jakob, 2016	3	4173	104-245	507/2099	267/2074	RR 1.88 (1.65-2.15)
<b>Fibrates</b>	Development of Diabetic Retinopathy	Jakob, 2016	2	1308	104-245	49/660	56/648	RR 0.6 (0.17-2.09)
<b>Fibrates</b>	Pancreatitis	Jakob, 2016	1	480	104	1/251	0/229	RR 2.74 (0.11-66.88)
<b>Fibrates</b>	Venous Thrombotic Events	Jakob, 2016	2	724	104	3/369	2/355	RR 1.46 (0.24-8.78)
<b>Fibrates</b>	Gallbladder Disease	Jakob, 2016	3	4805	104-261	19/2420	14/2385	RR 1.33 (0.68-2.62)
<b>Fibrates</b>	Myopathy	Wang, 2015	2	3138	52-624	7/1573	8/1565	RR 0.86 (0.31-2.39)
<b>Fibrates</b>	Altered Liver Function Tests	Wang, 2015	1	395	130	9/197	0/198	RR 19.1 (1.12-325.86)



<b>Fibrates</b>	GI Events	Wang, 2015	5	5593	130-313	1048/1941	2566/3652	RR 1.29 (0.78-2.14)
<b>Fibrates</b>	Raised Creatinine Concentration	Wang, 2015	1	1568	287	25/783	5/785	RR 5.01 (1.93-13.03)
<b>Niacin</b>	New-onset diabetes or worsening glucose tolerance	Garg, 2017	4	29330	NR	1006/14675=6.9%	712/14655=4.9%	RR 1.44 (1.31-1.59)
<b>Niacin</b>	New-onset Diabetes	Schandelmaier, 2017	3	27982	NR	529/14643	383/13339	RR 1.32 (1.16, 1.51)
<b>Niacin</b>	Gastrointestinal (abdominal pain, nausea, dyspepsia, diarrhea)	Garg, 2017	6	33203	NR	903/15800=5.7%	901/17403=5.2%	RR 1.53 (1.23-1.90)
<b>Niacin</b>	GI Symptoms	Schandelmaier, 2017	12	35353	NR	1087/17150	1006/18203	RR 1.69 (1.37-2.07)
<b>Niacin</b>	Musculoskeletal Events	Garg, 2017	4	26646	NR	484/13495=3.6%	388/13151=3.0%	RR 1.24 (1.09-1.42)
<b>Niacin</b>	Skin Flushing	Garg, 2017	7	33461	NR	1454/15933=9.1%	275/17528=1.6%	RR 18.59 (2.52-137.29)
<b>Niacin</b>	Flushing	Schandelmaier, 2017	15	11038	NR	1664/5146	223/5892	RR 7.69 (4.14-14.28)
<b>Niacin</b>	Liver Toxicity	Garg, 2017	6	4842	NR	14/2604=0.54%	6/2238=0.27%	RR 1.66 (0.65-4.27)
<b>Niacin</b>	Pruritus	Schandelmaier, 2017	6	5800	NR	649/2451	183/3349	RR 5.26 (2.68-10.32)
<b>Niacin</b>	Rash	Schandelmaier, 2017	9	31485	NR	424/15282	241/16203	RR 3.16 (1.94-5.13)

<b>Niacin</b>	Headache	Schandelmaier, 2017	3	300	NR	29/152	15/148	RR 1.40 (0.86-2.28)
<b>Omega 3s (EPA+DHA)</b>	Atrial Fibrillation	Gencer, 2021	6	73031	255	NR	NR	HR 1.23 (1.02-1.49)
<b>Omega 3s (EPA+DHA)</b>	Atrial Fibrillation	Khan, 2021	7	43157	NR	NR	NR	RR 1.14 (0.88-1.46)
<b>Omega 3s (EPA+DHA)</b>	GI Adverse Events	Khan, 2021	12	NR	NR	NR	NR	RR 1.18 (0.89-1.56)
<b>Omega 3s (EPA+DHA)</b>	Total Bleeding	Khan, 2021	10	NR	NR	NR	NR	RR 1.01 (0.97-1.05)
<b>EPA only</b>	Atrial Fibrillation	Khan, 2021	1	8179	NR	NR	NR	RR 1.35 (1.10-1.66)
<b>EPA only</b>	GI Adverse Events	Khan, 2021	3	27567	NR	NR	NR	RR 1.19 (0.75-1.89)
<b>EPA only</b>	Total Bleeding	Khan, 2021	2	27324	NR	NR	NR	RR 1.49 (1.20-1.84)
<b>PCSK-9 Inhibitors</b>	Increased serum transaminase	Bai, 2018	NR	20271	NR	NR	NR	RR 0.98 (0.84-1.14)
<b>PCSK-9 Inhibitors</b>	Elevated Creatine Kinase	Bai, 2018	NR	20237	NR	NR	NR	RR 0.85 (0.70-1.03)
<b>PCSK-9 Inhibitors</b>	Elevated Creatine Kinase	Karatasakis, 2017	34	44691	NR	279/24407	227/20284	OR 0.84 (0.70-1.01)
<b>PCSK-9 Inhibitors</b>	Elevated Creatine Kinase	Mu, 2020	20	NR	NR	NR	NR	RR 0.87 (0.73, 1.03)
<b>PCSK-9 Inhibitors</b>	Liver Enzyme Elevation	Guedeney, 2019	NR	63807	NR	565/34246	539/29561	RR 0.94 (0.84-1.06)

<b>PCSK-9 Inhibitors</b>	Increase in alanine or aspartate amino transferase	Karatasakis, 2017	33	44473	NR	350/24262	310/20211	OR 0.96 (0.82-1.12)
<b>PCSK-9 Inhibitors</b>	Aminotransferase Elevation (3x the normal level)	Toyota, 2019	4	53294	NR	511/27775	504/25519	OR 0.95 (0.84, 1.08)
<b>PCSK-9 Inhibitors</b>	Neurological Events	Bai, 2018	NR	3034	NR	NR	NR	RR 1.03 (0.82-1.30)
<b>PCSK-9 Inhibitors</b>	Neurocognitive Disorders	Bai, 2018	NR	20599	NR	NR	NR	RR 1.13 (0.95-1.34)
<b>PCSK-9 Inhibitors</b>	Neurocognitive Deficits	Bajaj, 2018	16	39065	NR	280/21214	227/17851	RR 1.11 (0.93-1.32)
<b>PCSK-9 Inhibitors</b>	Neurocognitive Adverse Events	Guedeney, 2019	NR	62480	NR	436/33229	399/29251	RR 1.01 (0.84-1.21)
<b>PCSK-9 Inhibitors</b>	Neurocognitive adverse events	Karatasakis, 2017	21	42668	NR	287/23167	231/19501	OR 1.12 (0.88-1.42)
<b>PCSK-9 Inhibitors</b>	Neurocognitive Adverse Events	Khan, 2019	6	54910	NR	416/28709	386/26201	RR 1.00 (0.85-1.18)
<b>PCSK-9 Inhibitors</b>	Neurocognitive Adverse Events	Mu, 2020	11	NR	NR	NR	NR	RR 0.98 (0.85-1.13)
<b>PCSK-9 Inhibitors</b>	Neurocognitive Impairment	Qin, 2021	5	54262	NR	459/28259	414/26003	RR 1.02 (0.81-1.29)
<b>PCSK-9 Inhibitors</b>	Neurocognitive Disorders	Talasaz, 2021	6	50759	NR	459/25940	420/24819	RR 0.99 (0.86-1.13)

<b>PCSK-9 Inhibitors</b>	Neurocognitive Effects	Turgeon, 2018	18	59035	NR	437/31430	397/27605	RR 1.02 (0.89, 1.16)
<b>PCSK-9 Inhibitors</b>	Cognitive Adverse Events	Lee, 2022	1	5337	110	53/2686	53/2651	RR 0.99 (0.68-1.44)
<b>PCSK-9 Inhibitors</b>	New onset or worsening diabetes	Bai, 2018	NR	17165	NR	NR	NR	RR 1.05 (0.96-1.16)
<b>PCSK-9 Inhibitors</b>	New onset or worsening diabetes	Karatasakis, 2017	15	27905	NR	859/15281	749/12624	OR 1.05 (0.95-1.17)
<b>PCSK-9 Inhibitors</b>	Incident Diabetes Mellitus	Khan, 2019	7	66030	NR	1708/34296	1538/31734	RR 1.00 (0.93-1.08)
<b>PCSK-9 Inhibitors</b>	New-onset Diabetes Mellitus	Lee, 2022	1	2968	110	114/1493	106/1475	RR 1.06 (0.82, 1.37)
<b>PCSK-9 Inhibitors</b>	New-onset Diabetes Mellitus	Monami, 2019	26	83835	NR	1751/43447	1724/40388	OR 1.00 (0.94-1.07)
<b>PCSK-9 Inhibitors</b>	New-onset Diabetes Mellitus	Mu, 2020	7	NR	NR	NR	NR	RR 1.00 (0.93-1.07)
<b>PCSK-9 Inhibitors</b>	New-onset Diabetes Mellitus	Talasaz, 2021	5	33166	NR	842/17093	742/16073	RR 1.14 (0.81-1.60)
<b>PCSK-9 Inhibitors</b>	New-onset or worsening diabetes mellitus	Turgeon, 2018	17	47701	NR	2047/25651	2025/22050	RR 0.96 (0.91, 1.02)
<b>PCSK-9 Inhibitors</b>	Injection Site Reactions	Guedeney, 2019	NR	61574	NR	1141/32587=3.5%	609/28987=2.1%	RR 1.41 (1.21-1.65)

<b>PCSK-9 Inhibitors</b>	Injection Site Reactions	Mu, 2020	20	NR	NR	NR	NR	RR 1.54 (1.38-1.71)
<b>PCSK-9 Inhibitors</b>	Injection Site Reactions	Talasaz, 2021	8	53933	NR	830/27532=3.0%	471/26401=1.8%	RR 2.11 (1.26-3.54)
<b>PCSK-9 Inhibitors</b>	Injection Site Reactions	Zhao, 2020	10	49536	NR	695/24998=2.8%	439/24538=1.8%	RR 1.55 (1.38-1.75)
<b>PCSK-9 Inhibitors</b>	Allergic Reactions	Guedeney, 2019	NR	52728	NR	1488/27207	1289/25521	RR 1.04 (0.97-1.12)
<b>PCSK-9 Inhibitors</b>	Myalgia	Karatasakis, 2017	23	14285	NR	400/9033	233/5252	OR 0.95 (0.75-1.20)
<b>PCSK-9 Inhibitors</b>	Myalgia	Mu, 2020	9	NR	NR	NR	NR	RR 1.09 (0.77-1.52)
<b>PCSK-9 Inhibitors</b>	Myalgia	Talasaz, 2021	5	33166	NR	842/17093	742/16073	RR 1.14 (0.81-1.60)
<b>PCSK-9 Inhibitors</b>	Muscle-related events	Turgeon, 2018	18	40867	NR	1463/22479	1058/18391	RR 1.00 (0.87, 1.15)
<b>PCSK-9 Inhibitors</b>	Myalgia	Turgeon, 2018	15	8737	NR	297/5650	158/3087	RR 1.05 (0.81, 1.36)
<b>PCSK-9 Inhibitors</b>	Rhabdomyolysis	Guedeney, 2019	NR	23526	NR	54/12242	54/11284	RR 0.90 (0.62-1.31)
<b>PCSK-9 Inhibitors</b>	Rhabdomyolysis	Toyota, 2019	1	27564	NR	8/13784	11/13780	OR 0.73 (0.29, 1.81)
<b>PCSK-9 Inhibitors</b>	Cancer	Khan, 2019	3	3962	NR	49/2631	38/1331	RR 0.54 (0.12-2.50)
<b>PCSK-9 Inhibitors</b>	Upper Respiratory Tract Infections	Mu, 2020	14	NR	NR	NR	NR	RR 0.97 (0.78-1.21)
<b>PCSK-9 Inhibitors</b>	Nasopharyngitis	Mu, 2020	13	NR	NR	NR	NR	RR 1.05 (0.87-1.27)

<b>Statins</b>	Muscle symptoms	Cai, 2021	21	65304	224	3459/36026= 9.6%	2785/29278= 9.5%	OR 1.06 (1.01- 1.13)
<b>Statins</b>	Any muscle problem (moderate dose vs placebo)	Davis, 2021	16	94635	NR	8110/47350= 17.1%	8028/47285= 17.0%	RR 1.01 (0.98, 1.04)
<b>Statins</b>	Any muscle problem (high dose vs placebo)	Davis, 2021	3	25466	NR	1682/12738= 13.2%	1633/12728= 12.8%	RR 1.03 (0.97, 1.10)
<b>Statins</b>	Statin associated muscle symptoms	Irwin, 2018	103	NR	68	NR	NR	RR 1.05 (1.01, 1.09)
<b>Statins</b>	Adverse muscle symptoms	Zhou, 2020	9	16633	52-209	642/8346= 7.7%	622/8287= 7.5%	RR 1.01 (0.90, 1.12)
<b>Statins</b>	Myalgia or muscle pain (moderate dose vs placebo)	Davis, 2021	9	62214	NR	276/31136= 0.9%	242/31078= 0.8%	RR 1.13 (0.95, 1.34)
<b>Statins</b>	Myalgia or muscle pain (high dose vs placebo)	Davis, 2021	3	25466	NR	919/12738= 7.2%	818/12728= 6.4%	RR 1.09 (0.94, 1.26)
<b>Statins</b>	Myalgia	Li, 2019	2	22533	NR	1550/11266= 13.8%	1516/11267= 13.5%	RR 1.02 (0.96- 1.09)
<b>Statins</b>	Myalgia	Singh, 2020	6	43134	NR	2009/21601= 9.3%	1896/21533= 8.8%	RR 1.02 (0.88- 1.19)

<b>Statins</b>	Myalgia or muscle pain	Taylor, 2013	9	37938	NR	1847/19396= 9.5%	1704/18542= 9.2%	RR 1.03 (0.97-1.09)
<b>Statins</b>	Attrition due to MSK complaints (moderate dose vs placebo)	Davis, 2021	8	62223	NR	224/31148= 0.7%	198/31075= 0.6%	RR 1.13 (0.93, 1.36)
<b>Statins</b>	Muscle disorders	Cai, 2021	25	85740	218	70/46746= 0.1%	55/38994= 0.1%	OR 0.88 (0.62,1.24)
<b>Statins</b>	Myopathy	Li, 2019	2	22533	NR	17/11266= 0.2%	16/11267= 0.1%	RR 1.06 (0.54-2.10)
<b>Statins</b>	Myopathy	Riaz, 2017	18	NR	NR	NR	NR	OR 1.20 (0.88, 1.62)
<b>Statins</b>	Myopathy	Singh, 2020	3	33365	NR	12/16690= 0.07%	11/16675= 0.07%	RR 1.09 (0.48-2.47)
<b>Statins</b>	Myopathy (CK >10X ULN)	Vale, 2014	3	4677	13-52	9/2355= 0.4%	1/2322= 0.04%	RR 4.69 (1.01-21.67)
<b>Statins</b>	Myopathy	Yebyo, 2019	16	NR	NR	NR	NR	RR 1.08 (1.01-1.15)
<b>Statins</b>	Myopathy	Zhou, 2020	7	13379	NR	4/6724= 0.06%	3/6655= 0.05%	NR
<b>Statins</b>	Liver dysfunction	Cai, 2021	21	54803	198	406/31305= 1.3%	217/23498= 0.9%	OR 1.33 (1.12, 1.58)
<b>Statins</b>	Hepatic disorder	Li, 2019	2	18071	NR	218/9035= 2.4%	186/9036= 2.1%	RR 1.17 (0.96-1.42)
<b>Statins</b>	Incidence of liver injury	Liang, 2018	16	74078	12-317	NR	NR	OR 1.18 (1.01, 1.39)
<b>Statins</b>	Hepatic dysfunction	Yebyo, 2019	12	NR	NR	NR	NR	RR 1.15 (1.01-1.31)

<b>Statins</b>	ALT/AST elevation	Li, 2019	3	22802	NR	82/11400=0.7%	32/11402=0.3%	RR 2.36 (1.00-5.60)
<b>Statins</b>	Elevated liver enzymes	Palmer, 2014	7	7991	NR	15/3969=0.4%	20/4022=0.5%	RR 0.76 (0.39-1.50)
<b>Statins</b>	AST/ALT elevation >2X ULN	Singh, 2020	6	38146	NR	256/19044=1.3%	215/19102=1.13%	RR 1.20 (1.00-1.43)
<b>Statins</b>	Elevated liver enzymes	Taylor, 2013	10	40094	NR	476/20420=2.3%	472/19674=2.4%	RR 1.16 (0.87-1.54)
<b>Statins</b>	ALT >3X ULN	Vale, 2014	5	11914	4-203	76/5980=1.3%	24/5934=0.40%	RR 2.49 (1.16-5.32)
<b>Statins</b>	Hyper-transaminase mia	Villani, 2019	73	123051	4-281	764/64227=1.2%	459/59113=0.8%	OR 1.45 (1.24, 1.69)
<b>Statins</b>	Diabetes	Li, 2019	3	28376	NR	425/14203=3.0%	350/14173=2.5%	RR 1.21(1.05-1.39)
<b>Statins</b>	Incidence Diabetes Mellitus	Singh, 2020	4	42804	NR	746/21369=3.5%	680/21435=3.2%	RR 1.10 (0.99-1.22)
<b>Statins</b>	Diabetes type 2	Yebyo, 2019	6	NR	NR	NR	NR	RR 1.04 (0.91-1.19)
<b>Statins</b>	Diabetes	Cai, 2021	9	58629	255	1190/29318=4.1%	1161/29311=4.0%	OR 1.01 (0.88, 1.16)
<b>Statins</b>	Incident diabetes type 2	Domecq, 2019	13	NR	245 (104-406)	NR	NR	RR 1.10 (1.03, 1.18)
<b>Statins</b>	Incident diabetes type 2	Engeda, 2019	8	78039	224	NR	NR	RR 1.11 (1.00, 1.22)



<b>Statins</b>	Incidence Diabetes Mellitus	Khan, 2019	16	92003	NR	2243/46039= 4.9%	2052/45964= 4.5%	RR 1.09 (1.03-1.16)
<b>Statins</b>	Incident diabetes type 2	Taylor, 2013	2	24407	NR	342/12205= 2.8%	290/12202= 2.4%	OR 1.18 (1.01-1.39)
<b>Statins</b>	Incident Diabetes Mellitus	Wang, 2017	14	95102	208	2392/47504= 5.0%	2167/47598= 4.6%	OR 1.11 (1.03, 1.20)
<b>Statins</b>	Renal insufficiency	Cai, 2021	8	32001	208	597/16858= 3.5%	520/15143= 3.4%	OR 1.14 (1.01, 1.28)
<b>Statins</b>	Renal disorder	Li, 2019	3	28376	NR	569/14203= 4.0%	508/14173= 3.6%	RR 1.12 (1.00-1.26)
<b>Statins</b>	Renal disorder	Taylor, 2013	4	27804	NR	563/14122= 4.0%	504/13682= 3.7%	OR 1.11 (0.99-1.26)
<b>Statins</b>	Renal disorder	Yebyo, 2019	3	NR	NR	NR	NR	RR 1.12 (1.00-1.26)
<b>Statins</b>	Eye conditions (cataracts and other eye related conditions)	Cai, 2021	6	25328	198	321/15282= 2.1%	234/10046= 2.3%	OR 1.23 (1.04, 1.47)
<b>Statins</b>	Rhabdomyolysis (moderate dose vs placebo)	Davis, 2021	14	76507	NR	15/38280= 0.04%	9/38227= 0.02%	RR 1.39 (0.68, 2.86)
<b>Statins</b>	Rhabdomyolysis (high dose vs placebo)	Davis, 2021	3	25535	NR	3/12770= 0.02%	3/12765= 0.02%	RR 0.96 (0.22, 4.09)
<b>Statins</b>	Rhabdomyolysis	Li, 2019	2	22533	NR	3/11266= 0.03%	3/11267= 0.03%	RR 0.95 (0.20-4.54)

<b>Statins</b>	Rhabdomyolysis (elevated CK)	Palmer, 2014	7	4514	NR	3/2226= 0.1%	5/2288= 0.2%	RR 0.84 (0.20-3.48)
<b>Statins</b>	Rhabdomyolysis	Singh, 2020	3	37112	NR	3/18566= 0.02%	2/18546= 0.01%	RR 1.29 (0.25-6.69)
<b>Statins</b>	Rhabdomyolysis	Taylor, 2013	6	38468	NR	3/19410= 0.02%	3/19058= 0.02%	RR 1.00 (0.23-4.38)
<b>Statins</b>	Rhabdomyolysis	Vale, 2014	1	4497	17	3/2265= 0.1%	0/2232= 0.0%	RR 6.9 (0.36-133.47)
<b>Statins</b>	Rhabdomyolysis	Zhou, 2020	7	15308	NR	1/7691= 0.01%	0/7617= 0%	NR
<b>Statins</b>	CK>10x ULN (moderate dose vs placebo)	Davis, 2021	11	61396	NR	46/30700= 0.1%	41/30696= 0.1%	RR 1.17 (0.72, 1.90)
<b>Statins</b>	CK>10x ULN (high dose vs placebo)	Davis, 2021	2	7733	NR	2/3869= 0.05%	0/3869= 0%	RR 2.73 (0.25, 30.11)
<b>Statins</b>	CK elevation	Li, 2019	2	5000	NR	3/2499= 0.1%	2/2501= 0.1%	RR 1.31 (0.14-12.22)
<b>Statins</b>	CK >10X ULN	Singh, 2020	4	17264		134/8583= 1.6%	130/8681= 1.5%	RR 0.88 (0.51-1.53)
<b>Statins</b>	Rhabdomyolysis, myalgia or rise in CK	Tramacere, 2019	3	6610	NR	4.6%	4.8%	OR 0.95 (0.75-1.19)
<b>Statins</b>	Gastrointestinal disorder	Li, 2019	2	18071	NR	1756/9035= 19.4%	1712/9036= 18.9%	RR 1.03 (0.97-1.09)
<b>Statins</b>	Cancer	Li, 2019	6	41970	NR	918/20974= 4.4%	921/20996= 4.4%	RR 0.99 (0.91-1.09)
<b>Statins</b>	Cancer	Palmer, 2014	2	5581	NR	139/2781= 5.0%	136/2800= 4.9%	RR 1.03 (0.82-1.30)

<b>Statins</b>	Any cancer	Singh, 2014	8	53830	NR	1168/26931= 4.3%	1204/26899= 4.5%	RR 0.97 (0.89- 1.05)
<b>Statins</b>	Cancer	Taylor, 2013	11	38739	NR	1180/19789= 6.0%	1075/18950= 5.7%	RR 1.01 (0.93- 1.10)
<b>Statins</b>	All cancers	Yebyo, 2019	9	NR	NR	NR	NR	RR 1.01 (0.94- 1.09)
<b>Statins</b>	Fatal cancer	Singh, 2014	4	39950	NR	211/19994= 1.1%	236/19956= 1.2%	RR 0.87 (0.61- 1.23)
<b>Statins</b>	Hemorrhagic stroke	Manktelow, 2009	2	8011	255-260	76/4010= 1.9%	44/4001= 1.1%	OR 1.72 (1.20- 2.46)
<b>Statins</b>	Hemorrhagic stroke	Taylor, 2013	2	25634	NR	22/12767= 0.2%	23/12867= 0.2%	OR 0.97 (0.54- 1.75)
<b>Statins</b>	Hemorrhagic stroke	Tramacere, 2019	6	9976	NR	1.8%	1.2%	OR 1.54 (1.10- 2.15)
<b>Statins</b>	Hemorrhagic stroke	Yin, 2022	7	10255	5days-260 weeks	100/5106= 2.0%	81/5119= 1.6%	OR 1.15 (0.62- 2.13)
<b>Statins</b>	Headache or nausea	Yebyo, 2019	5	NR	NR	NR	NR	RR 1.13 (0.97- 1.31)